8-K Announcements
6Material company update
Mar 19, 2026·SEC
Material company update
Feb 2, 2026·SEC
Material company update
Jan 8, 2026·SEC
Genelux Corporation(GNLX)Earnings, Financials & Key Ratios
GNLX•NASDAQ
Price updated Jun 19, 2026
AboutGenelux Corporation, a clinical-stage biopharmaceutical company, focuses on developing next-generation oncolytic viral immunotherapies for patients suffering from aggressive and/or difficult-to-treat solid tumor types. Its lead product candidate is Olvi-Vec, a proprietary, modified strain of the vaccinia virus for the treatment of ovarian cancer and non-small-cell lung cancer. The company is also developing V2ACT Immunotherapy for the treatment of pancreatic cancer; and V-VET1 to treat hematologic and solid cancer. The company was incorporated in 2001 and is headquartered in Westlake Village, California.Show more
- Revenue$8K
- EBITDA-$33M-6.0%
- Net Income-$32M-7.6%
- EPS (Diluted)-0.86+9.5%
- Gross Margin-7075%+36.8%
- EBITDA Margin-408000%-6.0%
- Operating Margin-415175%-4.8%
- Net Margin-401812.5%-7.6%
- ROE-170%-30.2%
GNLX Key Insights
Genelux Corporation (GNLX) fundamental analysis — strengths, weaknesses & financial health based on data analysis
✓Strengths
No significant strengths identified
✗Weaknesses
- ✗Profits declining 16.7% over 5 years
- ✗Weak Piotroski F-Score: 3/9
- ✗Negative free cash flow
- ✗Shares diluted 18.2% in last year
- ✗Trading more than 30% below 52-week high
- ✗Low asset turnover indicates capital-intensive operations
* These insights are generated automatically based on available financial data. Please conduct your own research before making investment decisions.
Get notified when GNLX posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
GNLX Price & Volume
Genelux Corporation (GNLX) stock price & volume — 10-year historical chart
Loading chart...
GNLX Growth Metrics
Genelux Corporation (GNLX) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR
Revenue CAGR
10 Years-
5 Years-
3 Years-91.03%
TTM-
Profit CAGR
10 Years-
5 Years-
3 Years-
TTM-7.68%
EPS CAGR
10 Years-
5 Years-
3 Years-
TTM1.12%
Return on Capital
10 Years-135.26%
5 Years-135.26%
3 Years-135.26%
Last Year-163.56%
GNLX Recent Earnings
Genelux Corporation (GNLX) EPS & revenue vs analyst estimates — last 4 quarters
●Beat EPS 3/12 qtrs (25%)●Beat Revenue 0/12 qtrs (0%)
Q2 2026Latest
May 7, 2026Metric
Actual
Est
EPS
$0.20-11.1%
$0.18
Rev
—
—
Q2 2026
Mar 19, 2026Metric
Actual
Est
EPS
$0.24-9.1%
$0.22
Rev
$8,000+0.0%
$8,000
Q4 2025
Nov 5, 2025Metric
Actual
Est
EPS
$0.21+8.7%
$0.23
Rev
—
—
Q3 2025
Aug 7, 2025Metric
Actual
Est
EPS
$0.20+9.1%
$0.22
Rev
—
—
| Quarter | Date | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|---|
| Q2 2026Latest | May 7, 2026 | $0.20vs $0.18-11.1% | — |
| Q2 2026 | Mar 19, 2026 | $0.24vs $0.22-9.1% | $8,000vs $8,000+0.0% |
| Q4 2025 | Nov 5, 2025 | $0.21vs $0.23+8.7% | — |
| Q3 2025 | Aug 7, 2025 | $0.20vs $0.22+9.1% | — |
Based on last 12 quarters of dataView full earnings history →
GNLX Peer Comparison
Genelux Corporation (GNLX) competitors in Oncology Therapeutics Developers — business model, growth, and fundamentals comparison
| Company | Market Cap | Stock Price | P/E Ratio (TTM) | Revenue Growth 1Y | Net Margin | Return on Equity (ROE) | FCF Yield | Debt / Equity |
|---|---|---|---|---|---|---|---|---|
 IMVT | 7.26B | 35.34 | -12.76 | -68.16% | 0.00 | |||
 TGTX | 8.15B | 53.22 | 19.21 | 87.32% | 65.95% | 87.36% | 0.40 | |
 KRYS | 10.26B | 348.06 | 50.89 | 33.94% | 53.92% | 19.25% | 0.01 | |
 ADCT | 138.64M | 1.09 | -0.97 | 14.85% | -173.02% | |||
 VVOS | 2.94M | 0.50 | -0.24 | 16.05% | -128.36% | -23.38% | ||
 IMCR | 1.45B | 28.60 | -53.96 | 20% | -4.88% | -4.83% | 0.11 | |
 CLDX | 2.16B | 32.43 | -8.32 | -78.63% | -345.96% | -50.72% | 0.00 | |
 NKTR | 1.19B | 60.98 | -6.27 | -43.89% | -284.18% | -87% | 1.66 |
Compare GNLX vs Peers
Genelux Corporation (GNLX) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
GNLX Income Statement
Genelux Corporation (GNLX) annual income statement — 10-year revenue, gross profit & net income history
10Y historyFree accessUpdated daily
| Metric | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 | TTM |
|---|---|---|---|---|---|---|---|---|
Sales/Revenue | 0 | 0 | 0 | 11.07M | 170K | 8K | 8K | 8K |
Revenue Growth % | - | - | - | - | -98.46% | -95.29% | 0% | - |
Cost of Goods Sold | 0 | 658K | 895K | 968K | 1.02M | 903K | 574K | 292K |
COGS % of Revenue | - | - | - | 8.75% | 598.82% | 11287.5% | 7175% | - |
Gross Profit | 0▲ 0% | -658K▲ 0% | -895K▼ 36.0% | 10.1M▲ 1228.5% | -848K▼ 108.4% | -895K▼ 5.5% | -566K▲ 36.8% | -284K▲ 0% |
Gross Margin % | - | - | - | 91.25% | -498.82% | -11187.5% | -7075% | -3550% |
Gross Profit Growth % | - | - | -36.02% | 1228.49% | -108.4% | -5.54% | 36.76% | - |
Operating Expenses | 10.87M | 11.76M | 13.72M | 13.11M | 23.32M | 30.8M | 32.65M | 33.48M |
OpEx % of Revenue | - | - | - | 118.48% | 13715.88% | 385012.5% | 408100% | - |
Selling, General & Admin | 3.34M | 6.2M | 8.29M | 5M | 11.57M | 12.71M | 13.37M | 13.37M |
SG&A % of Revenue | - | - | - | 45.2% | 6804.71% | 158825% | 167137.5% | - |
Research & Development | 7.53M | 6.23M | 6.32M | 9.08M | 12.77M | 19M | 19.85M | 20.4M |
R&D % of Revenue | - | - | - | 82.02% | 7510% | 237475% | 248137.5% | - |
Other Operating Expenses | 0 | -658K | -895K | -968K | -1.02M | -903K | -574K | -291K |
Operating Income | -10.87M▲ 0% | -12.42M▼ 14.3% | -14.61M▼ 17.6% | -3.01M▲ 79.4% | -24.16M▼ 702.0% | -31.7M▼ 31.2% | -33.21M▼ 4.8% | -33.76M▲ 0% |
Operating Margin % | - | - | - | -27.22% | -14214.71% | -396200% | -415175% | -422037.5% |
Operating Income Growth % | - | -14.28% | -17.64% | 79.38% | -702.02% | -31.16% | -4.79% | - |
EBITDA | -10.49M | -11.76M | -13.72M | -2.04M | -23.15M | -30.79M | -32.64M | -33.28M |
EBITDA Margin % | - | - | - | -18.48% | -13615.88% | -384912.5% | -408000% | -416037.5% |
EBITDA Growth % | - | -12.1% | -16.61% | 85.09% | -1031.88% | -33.03% | -6% | -8.76% |
D&A (Non-Cash Add-back) | 376K | 658K | 895K | 968K | 1.02M | 903K | 574K | 480K |
EBIT | -10.87M | -12.42M | -14.56M | -2.7M | -27.48M | -29.87M | -33.21M | -33.76M |
Net Interest Income | -761K | -1.22M | -1.81M | -1.41M | -3.73M | 1.46M | 1.07M | 1.99M |
Interest Income | 0 | 0 | 0 | 0 | 244K | 1.46M | 1.07M | 1.99M |
Interest Expense | 761K | 1.22M | 1.81M | 1.41M | 3.97M | 0 | 0 | 0 |
Other Income/Expense | -761K | -1.22M | -1.76M | -1.09M | -4.13M | 1.83M | 1.07M | 1.99M |
Pretax Income | -11.63M▲ 0% | -13.64M▼ 17.3% | -16.38M▼ 20.0% | -4.11M▲ 74.9% | -28.3M▼ 589.0% | -29.87M▼ 5.6% | -32.15M▼ 7.6% | -31.78M▲ 0% |
Pretax Margin % | - | - | - | -37.11% | -16645.29% | -373362.5% | -401812.5% | -397225% |
Income Tax | 0 | 0 | 0 | 1.1M | 0 | 0 | 0 | 0 |
Effective Tax Rate % | 0% | 0% | 0% | -26.78% | 0% | 0% | 0% | 0% |
Net Income | -11.63M▲ 0% | -14.86M▼ 27.8% | -17.8M▼ 19.7% | -5.21M▲ 70.7% | -28.3M▼ 443.4% | -29.87M▼ 5.6% | -32.15M▼ 7.6% | -31.78M▲ 0% |
Net Margin % | - | - | - | -47.05% | -16645.29% | -373362.5% | -401812.5% | -397225% |
Net Income Growth % | - | -27.8% | -19.72% | 70.74% | -443.44% | -5.56% | -7.62% | -7.68% |
Net Income (Continuing) | -11.63M | -13.64M | -16.38M | -5.21M | -28.3M | -29.87M | -32.15M | -31.78M |
Discontinued Operations | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
EPS (Diluted) | -0.49▲ 0% | -0.58▼ 18.4% | -0.69▼ 19.0% | -0.21▲ 69.6% | -1.16▼ 452.4% | -0.95▲ 18.1% | -0.86▲ 9.5% | -0.98▲ 0% |
EPS Growth % | - | -18.37% | -18.97% | 69.57% | -452.38% | 18.1% | 9.47% | 1.12% |
EPS (Basic) | -0.49 | -0.58 | -0.69 | -0.21 | -1.16 | -0.95 | -0.86 | - |
Diluted Shares Outstanding | 23.62M | 23.62M | 23.62M | 24.55M | 24.43M | 31.45M | 37.18M | 32.5M |
Basic Shares Outstanding | 23.62M | 23.62M | 23.62M | 24.55M | 24.43M | 31.45M | 37.18M | 32.5M |
Dividend Payout Ratio | - | - | - | - | - | - | - | - |
GNLX Balance Sheet
Genelux Corporation (GNLX) balance sheet — assets, liabilities & shareholders' equity
| Metric | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 | TTM |
|---|---|---|---|---|---|---|---|---|
Total Current Assets | 551K | 11.48M | 5.82M | 1.89M | 24.2M | 31.55M | 15.13M | 26.75M |
Cash & Short-Term Investments | 425K | 11.35M | 4.5M | 397K | 23.19M | 30.89M | 14.6M | 26.21M |
Cash Only | 425K | 11.35M | 4.5M | 397K | 9.42M | 8.56M | 5.33M | 9.27M |
Short-Term Investments | 0 | 0 | 0 | 0 | 13.77M | 22.33M | 9.26M | 16.94M |
Accounts Receivable | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Days Sales Outstanding | - | - | - | - | - | - | - | - |
Inventory | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Days Inventory Outstanding | - | - | - | - | - | - | - | - |
Other Current Assets | 126K | 0 | 0 | 1.5M | 1.01M | 653K | 535K | 545K |
Total Non-Current Assets | 2.73M | 2.53M | 2.3M | 3.64M | 3.69M | 3.17M | 3.9M | 5.62M |
Property, Plant & Equipment | 2.65M | 2.45M | 2.21M | 1.98M | 3.6M | 3.08M | 3.75M | 5.47M |
Fixed Asset Turnover | - | - | - | 5.59x | 0.05x | 0.00x | 0.00x | 0.00x |
Goodwill | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Intangible Assets | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Long-Term Investments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Other Non-Current Assets | 80K | 80K | 92K | 1.66M | 92K | 92K | 144K | 144K |
Total Assets | 3.28M▲ 0% | 14.01M▲ 326.9% | 8.13M▼ 42.0% | 5.53M▼ 31.9% | 27.89M▲ 404.3% | 34.72M▲ 24.5% | 19.03M▼ 45.2% | 32.37M▲ 0% |
Asset Turnover | - | - | - | 2.00x | 0.01x | 0.00x | 0.00x | 0.00x |
Asset Growth % | - | 326.94% | -41.99% | -31.93% | 404.3% | 24.46% | -45.19% | -128.73% |
Total Current Liabilities | 14.73M | 14.49M | 22.48M | 31.63M | 6.55M | 6.9M | 6.22M | 7.27M |
Accounts Payable | 0 | 927K | 4.46M | 6.78M | 3.78M | 5.57M | 0 | 0 |
Days Payables Outstanding | - | 514.22 | 1.82K | 2.55K | 1.36K | 2.25K | - | 1.89K |
Short-Term Debt | 4.61M | 3.6M | 6.16M | 16.4M | 0 | 329K | 427K | 316K |
Deferred Revenue (Current) | 0 | 0 | 4.5M | 170K | 0 | 0 | 0 | 0 |
Other Current Liabilities | 10.12M | 6.84M | 4.11M | 5.16M | 0 | 0 | 5.8M | 6.96M |
Current Ratio | 0.04x | 0.79x | 0.26x | 0.06x | 3.69x | 4.57x | 2.43x | 3.68x |
Quick Ratio | 0.04x | 0.79x | 0.26x | 0.06x | 3.69x | 4.57x | 2.43x | 3.68x |
Cash Conversion Cycle | - | - | - | - | - | - | - | - |
Total Non-Current Liabilities | 13.37M | 22.17M | 18.75M | 9.69M | 1.87M | 1.54M | 1.26M | 2.18M |
Long-Term Debt | 13.04M | 21.69M | 18.02M | 8.52M | 0 | 0 | 1.26M | 2.18M |
Capital Lease Obligations | 322K | 476K | 731K | 1.16M | 1.87M | 1.54M | 0 | 1.36M |
Deferred Tax Liabilities | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Other Non-Current Liabilities | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Total Liabilities | 28.09M | 36.66M | 41.24M | 41.31M | 8.42M | 8.44M | 7.48M | 9.45M |
Total Debt | 17.97M | 26.06M | 25.31M | 26.35M | 2.52M | 1.87M | 1.69M | 2.5M |
Net Debt | 17.55M | 14.71M | 20.82M | 25.96M | -6.9M | -6.7M | -3.65M | -6.78M |
Debt / Equity | - | - | - | - | 0.13x | 0.07x | 0.15x | 0.11x |
Debt / EBITDA | - | - | - | - | - | - | - | -0.07x |
Net Debt / EBITDA | - | - | - | - | - | - | - | 0.20x |
Interest Coverage | -14.28x | -10.17x | -8.02x | -1.92x | -6.91x | - | - | - |
Total Equity | -24.81M▲ 0% | -22.66M▲ 8.7% | -33.11M▼ 46.2% | -35.78M▼ 8.1% | 19.47M▲ 154.4% | 26.27M▲ 34.9% | 11.54M▼ 56.1% | 22.92M▲ 0% |
Equity Growth % | - | 8.69% | -46.15% | -8.07% | 154.42% | 34.93% | -56.06% | -159.64% |
Book Value per Share | -1.05 | -0.96 | -1.40 | -1.46 | 0.80 | 0.84 | 0.31 | 0.71 |
Total Shareholders' Equity | -24.81M | -22.66M | -33.11M | -35.78M | 19.47M | 26.27M | 11.54M | 22.92M |
Common Stock | 24K | 27K | 9K | 9K | 27K | 35K | 38K | 45K |
Retained Earnings | -154.59M | -168.23M | -184.58M | -189.78M | -221.52M | -251.39M | -283.54M | -292.47M |
Treasury Stock | -1.3M | -1.3M | -433K | -433K | -433K | -433K | 0 | 0 |
Accumulated OCI | 2K | 2K | 2K | 2K | 14K | 64K | 9K | -5K |
Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
GNLX Cash Flow Statement
Genelux Corporation (GNLX) cash flow — operating, investing & free cash flow history
| Metric | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 | TTM |
|---|---|---|---|---|---|---|---|---|
Cash from Operations | -7.22M | -7.21M | -6.58M | -3.57M | -20.27M | -21.23M | -25.27M | -25.89M |
Operating CF Margin % | - | - | - | -32.26% | -11926.47% | -265350% | -315850% | - |
Operating CF Growth % | - | 0.25% | 8.61% | 45.77% | -467.77% | -4.7% | -19.03% | -73.41% |
Net Income | -11.63M | -13.64M | -16.38M | -5.21M | -28.3M | -29.87M | -32.15M | -31.78M |
Depreciation & Amortization | 477K | 658K | 895K | 968K | 1.02M | 903K | 244K | 44K |
Stock-Based Compensation | 0 | 5.33M | 4.27M | 2.42M | 5.2M | 6.07M | 5.87M | 5.84M |
Deferred Taxes | 0 | 0 | 348K | 0 | 0 | 0 | 0 | 0 |
Other Non-Cash Items | 3.85M | 74K | 196K | -56K | 5.08M | 917K | 1.81M | 3.38M |
Working Capital Changes | 84K | 381K | 4.08M | -1.69M | -3.28M | 751K | -1.05M | -1.57M |
Change in Receivables | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Change in Inventory | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Change in Payables | 0 | -126K | 754K | 2.31M | -2.36M | 2.16M | -1.21M | -594K |
Cash from Investing | -1.77M | -20K | 0 | -49K | -14.72M | -8.13M | 12.14M | 93K |
Capital Expenditures | -1.77M | -20K | 0 | -49K | -1.02M | -381K | -1.1M | -1.99M |
CapEx % of Revenue | - | - | - | 0.44% | 602.94% | 4762.5% | 13725% | 24862.5% |
Acquisitions | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Investments | - | - | - | - | - | - | - | - |
Other Investing | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Cash from Financing | 7.89M | 18.15M | -270K | -478K | 44.02M | 28.51M | 9.89M | 18.87M |
Debt Issued (Net) | 1.5M | 9.16M | -558K | 970K | 215K | 0 | 0 | 0 |
Equity Issued (Net) | 6.38M | 8.99M | 143K | 0 | 39.65M | 27.82M | 9.89M | 328K |
Dividends Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Share Repurchases | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Other Financing | 0 | 0 | 145K | -1.45M | 4.16M | 688K | 0 | 18.54M |
Net Change in Cash | -1.11M▲ 0% | 10.93M▲ 1087.8% | -6.86M▼ 162.7% | -4.1M▲ 40.2% | 9.02M▲ 320.1% | -853K▼ 109.5% | -3.23M▼ 278.9% | -6.93M▲ 0% |
Free Cash Flow | -8.99M▲ 0% | -7.22M▲ 19.7% | -6.58M▲ 8.9% | -3.62M▲ 45.0% | -21.3M▼ 488.4% | -21.61M▼ 1.5% | -26.37M▼ 22.0% | -27.88M▲ 0% |
FCF Margin % | - | - | - | -32.71% | -12529.41% | -270112.5% | -329575% | -348512.5% |
FCF Growth % | - | 19.67% | 8.86% | 45.03% | -488.4% | -1.45% | -22.01% | -22.88% |
FCF per Share | -0.38 | -0.31 | -0.28 | -0.15 | -0.87 | -0.69 | -0.71 | -0.86 |
FCF Conversion (FCF/Net Income) | 0.62x | 0.48x | 0.37x | 0.69x | 0.72x | 0.71x | 0.79x | 0.88x |
Interest Paid | 0 | 0 | 0 | 264K | 0 | 0 | 0 | 0 |
Taxes Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
GNLX Key Ratios
Genelux Corporation (GNLX) financial ratios — P/E, ROE, debt and 30+ core market and balance-sheet ratios
| Metric | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|
Return on Equity (ROE) | - | - | - | -145.31% | -130.58% | -170% | -165.18% |
Return on Invested Capital (ROIC) | - | - | - | -1319.53% | -147.88% | -181.35% | -172.79% |
Gross Margin | - | - | 91.25% | -498.82% | -11187.5% | -7075% | -3550% |
Net Margin | - | - | -47.05% | -16645.29% | -373362.5% | -401812.5% | -397225% |
Debt / Equity | - | - | - | 0.13x | 0.07x | 0.15x | 0.11x |
Interest Coverage | -10.17x | -8.02x | -1.92x | -6.91x | - | - | - |
FCF Conversion | 0.48x | 0.37x | 0.69x | 0.72x | 0.71x | 0.79x | 0.88x |
Revenue Growth | - | - | - | -98.46% | -95.29% | 0% | - |
Related:GNLX Dividend History·GNLX Revenue History·GNLX Price History·GNLX P/E History·GNLX Financial Ratios·GNLX Institutional Holders
GNLX SEC Filings & Documents
Genelux Corporation (GNLX) SEC filings — annual & quarterly reports (10-K, 10-Q)
GNLX Frequently Asked Questions
Genelux Corporation (GNLX) stock FAQ — growth, dividends, profitability & financials explained
Growth & Financials
Genelux Corporation (GNLX) reported $0.0M in revenue for fiscal year 2025.
Genelux Corporation (GNLX) grew revenue by 0.0% over the past year. Growth has been modest.
Genelux Corporation (GNLX) reported a net loss of $31.8M for fiscal year 2025.
Dividend & Returns
Genelux Corporation (GNLX) has a return on equity (ROE) of -170.0%. Negative ROE indicates the company is unprofitable.
Genelux Corporation (GNLX) had negative free cash flow of $27.9M in fiscal year 2025, likely due to heavy capital investments.